Navigation Links
Dynavax Reports Progress in Lupus Program With Inhibitor of TLR7 and TLR9
Date:11/26/2007

lliance for Lupus Research awarded to Dynavax a $500,000 grant to explore new treatment approaches for systemic lupus erythematosus based on the company's novel IRS technology. The grant was the first time ALR had provided funding to a private company.

About Dynavax

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Our product candidates include: HEPLISAVTM, a hepatitis B vaccine in Phase 3 partnered with Merck & Co. Inc.; TOLAMBATM, a ragweed allergy immunotherapy in Phase 2; a therapy for non-Hodgkin's lymphoma (NHL) in Phase 2 and for metastatic colorectal cancer in Phase 1; and a therapy for hepatitis B also in Phase 1. Our preclinical asthma and COPD program is partnered with AstraZeneca. The National Institutes of Health (NIH) partially funds our preclinical work on a vaccine for influenza. Symphony Dynamo, Inc. (SDI) funds our colorectal cancer trials and our preclinical hepatitis C therapeutic program, and Deerfield Management has committed funding for our allergy programs. While Deerfield, NIH and SDI provide program support, Dynavax has retained rights to seek strategic partners for future development and commercialization. For more information, please visit http://www.dynavax.com.

This press release contains forward-looking statements that are subject to a number of risks and uncertainties, including statements about the potential for our IRS as an approach for the treatment of lupus and multiple autoimmune diseases. Actual results
'/>"/>

SOURCE Dynavax Technologies Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
2. Dynavax to Present at UBS 2007 Global Life Sciences Conference
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. QMed, Inc. Reports July Medicare SNP Enrollments
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2015)... According to a new market research ... & Non-Portable), Component (Accelerometer, Proximity Probe, & Others), ... Mining, & Others), & Geography - Global Forecast ... reach $1,453.76 Million by 2020, at a CAGR ... and 92 figures spread through 205 pages and ...
(Date:4/29/2015)... (TSX-V: BRM) ("Biorem" or "the Company") today announced its results for the ... year-end financial statements and MD&A have been filed on SEDAR ( www.sedar.com ... 2014 , 2013 Revenue 3,968 , 5,121 ... , 1,703 , 2,231 , 5,866 Operating  ... , 4,562 Ebitda* 92 , 418 , ...
(Date:4/29/2015)... 29, 2015 Cambrex Corporation (NYSE: CBM ) ... on Friday, May 1, 2015 before the market opens. ... will host a conference call to discuss the financial results. ... , Friday, May 1, 2015 at 8:30 a.m. ... for U.S.1-719-325-2454 for International  Passcode:  7993632 Dial-in Replay: ...
(Date:4/29/2015)... The leading Regenerative Veterinary Medicine Company, VetStem Biopharma., ... therapy has processed more than 11,000 samples. VetStem ... treatment for horses with potentially fatal injuries to tendons ... exclusive license for adipose-derived (fat derived) stem cell technology ... in January 2004. Shortly after, the first dogs were ...
Breaking Biology Technology:Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 2Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 4Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4VetStem Biopharma -Regenerative Cell Therapy has processed over 11,000 samples 2
... Dec. 21 Ipsogen SA (Alternext: ALIPS) today announced ... tumor grade in chemotherapy prescription has been presented at ... December 9-13, 2009. , The study was conducted ... Using the centre database and a classification tree method, ...
... , - Company,s results amongst the ... CITY, Dec. 21 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG) ... affordable vaccines based on proprietary manufacturing technologies and Virus-Like ... Phase I human clinical trial with its H5N1 Avian ...
... METTLER TOLEDO recently ... FTIR Analytics as a Process Analytical Technology (PAT), on January 20, 2010. , ... (PRWEB) December 20, 2009 -- METTLER TOLEDO ... In Situ FTIR Analytics as a Process Analytical Technology (PAT), on January 20, ...
Cached Biology Technology:Institut Paoli Calmettes and Ipsogen Presented a New Study Supporting the Pivotal Role of Tumor Grade in Chemotherapy Prescription at the 32nd Annual San Antonio Breast Cancer Symposium 2Medicago reports positive Phase I results for its avian flu pandemic vaccine 2Medicago reports positive Phase I results for its avian flu pandemic vaccine 3Medicago reports positive Phase I results for its avian flu pandemic vaccine 4Real Time to Manufacturing Using Real-Time In Situ FTIR Analytics as a Process Analytical Technology (PAT) Tool 2
(Date:4/14/2015)... 14, 2015  HYPR Corp. today announced it ... ) Alliance tm , an industry consortium transforming ... to share technology and collaborate to deliver open ... more secure and private, and easier to use. ... that protects sensitive user information and eliminates the ...
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... April 23, 2015, after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
(Date:4/2/2015)... Sweden , April 2, 2015 ... for Q1 2015 attributed to somewhat higher than 125 ... in the year-end report 2014 that revenues for Q1 ... that the company reported for Q4 2014. The operating ... to be negative. The complete interim report will as ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... animal models is enabling a deeper understanding of the ... that may lead to more effective treatment options to ... The findings were released today at Neuroscience 2009, the ... source of emerging news about brain science and health. ...
... a child,s speech development if the habit goes on ... in Patagonia, Chile, researchers associated the persistence of these ... in preschool children. The children were more likely to ... their pronunciation. The results were published Wednesday, Oct. ...
... the environmental equivalent of the ASX200 as a means of ... of an ecosystem can be understood by measuring the right ... of the Australian stock market by following 200 selected stocks. ... Hayes, one of the leaders of the project, says the ...
Cached Biology News:Studies improve knowledge of underlying brain changes caused by addiction 2Infant sucking habits may affect how baby talks 2Finding the ASX200 for marine ecosystems 2
VACUGENE PUMP 110V, 1 EA. Category: Nucleid Acid Detection Systems....
... ES1301 mutS are mismatch repair minus strains ... prevents repair of the newly synthesized unmethylated ... and making them helpful in such systems ... Mutagenesis Systems. Both ES1301 and BMH 71-18 ...
Request Info...
Anti-Rat KAPPA/LAMBDA:HRP, Clone MARK-1/MARL-15, Monoclonal Antibody...
Biology Products: